Purple Biotech (PPBT) Cash from Investing Activities (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Cash from Investing Activities of $45000.0 for Q1 2026, down 82.49% year-over-year from $257000.0 in Q1 2025, and up 143.27% quarter-over-quarter from -$104000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Investing Activities (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Cash from Investing Activities for 10 consecutive years, with $45000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 82.49% year-over-year to $45000.0; the TTM figure through Mar 2026 stood at $420000.0 (down 7.49% YoY), while the FY2025 annual figure was $632000.0, up 24.17% from the prior year.
- Cash from Investing Activities advanced to $45000.0 in Q1 2026 per PPBT's latest filing, from -$104000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $17.7 million in Q1 2022 and bottomed at -$6.0 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged $2.1 million across 5 years, with a median of $177000.0 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities soared 1249.28% — and 2025, when it sank 373.68%.
- Purple Biotech's Cash from Investing Activities stood at $8.0 million in 2022, then slumped by 99.07% to $74000.0 in 2023, then sank by 48.65% to $38000.0 in 2024, then sank by 373.68% to -$104000.0 in 2025, then soared by 143.27% to $45000.0 in 2026.
- Business Quant data shows PPBT's Cash from Investing Activities at $45000.0 in Q1 2026, -$104000.0 in Q4 2025, and $372000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45,000.00 |
| Mar 31, 2026 | 45,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Dec 31, 2025 | -104,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Jun 30, 2025 | 107,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Sep 30, 2024 | 72,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 312,000.00 |
| Mar 31, 2024 | 312,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Dec 31, 2023 | 74,000.00 |